



(51) International Patent Classification:

B01D 15/36 (2006.01) *A61P 31/14* (2006.01)
C12N 7/00 (2006.01)

(21) International Application Number:

PCT/US2023/061238

(22) International Filing Date:

25 January 2023 (25.01.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/302,910	25 January 2022 (25.01.2022)	US
63/302,920	25 January 2022 (25.01.2022)	US
63/385,274	29 November 2022 (29.11.2022)	US
63/385,309	29 November 2022 (29.11.2022)	US

(71) Applicant: **TAKEDA VACCINES, INC.** [US/US]; 75 Sidney Street, Cambridge, Massachusetts 02139 (US).

(72) Inventors: **KHOO, Gary**; c/o Takeda Vaccines Private Limited, 21 Biopolis Road, Nucleos North Tower, Level 4, Singapore 138567 (SG). **LOH, Jia Vern**; c/o Takeda Vaccines Private Limited, 21 Biopolis Road, Nucleos

North Tower, Level 4, Singapore 138567 (SG). **LIVEN-GOOD, Jill A.**; c/o Takeda Vaccines, Inc., 75 Sidney Street, CAMBRIDGE, Massachusetts 02139 (US). **SANTANGELO, Joseph David**; c/o Takeda Vaccines, Inc., 75 Sidney Street, CAMBRIDGE, Massachusetts 02139 (US). **SEAH, Kwee Loong**; c/o Takeda Vaccines Private Limited, 21 Biopolis Road, Nucleos North Tower, Level 4, Singapore 138567 (SG). **LUO, Weiwen**; c/o Takeda Vaccines Private Limited, 21 Biopolis Road, Nucleos North Tower, Level 4, Singapore 138567 (SG). **LEE, Yockann**; c/o Takeda Vaccines Private Limited, 21 Biopolis Road, Nucleos North Tower, Level 4, Singapore 138567 (SG).

(74) Agent: **ALBERDI, PH.D., Fernando**; Honigman LLP, 650 Trade Centre Way, Suite 200, Kalamazoo, Michigan 49002-0402 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG,

(54) Title: LARGE-SCALE FLAVIVIRAL VACCINE PRODUCTION AND MANUFACTURE




FIG. 1

(57) Abstract: The present invention provides methods for large-scale flaviviral vaccine production and manufacture. The methods provided herein are specifically contemplated for large-scale production and manufacture of live, attenuated flaviviral vaccines such as live, attenuated, dengue virus vaccines. Further, the methods provided herein pertain to formulation of live, attenuated, monovalent, divalent, trivalent, or tetravalent viral vaccine products.

[Continued on next page]

NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS,
RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to the identity of the inventor (Rule 4.17(i))*

Published:

— *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*
— *with sequence listing part of description (Rule 5.2(a))*